Amitriptyline for the Treatment of Extra-esophageal Symptoms in Proton Pump Inhibitor-refractory Patients With Suspected Gastroesophageal Reflux Disease
Abstract
Background/AimsGastroesophageal reflux disease (GERD) is a chronic, heterogeneous condition that impairs quality of life.Extraesophageal symptoms (eg, globus sensation, chronic cough, hoarseness, wheezing) often persist despite proton pump inhibitor (PPI) therapy.Tricyclic antidepressants are recommended for such refractory cases, but supporting evidence is limited.This study aimed to evaluate the efficacy of low-dose amitriptyline in treating extraesophageal GERD symptoms. MethodsWe conducted a single-center, single-blind, randomized, controlled crossover pilot trial (2016-2021).Forty patients with typical GERD symptoms plus ≥ 1 atypical symptom (eg, globus, cough) unresponsive to ≥ 4 weeks of PPI therapy were randomized to receive either lansoprazole 30 mg daily plus amitriptyline 10 mg at bedtime or lansoprazole alone for 4 weeks, followed by crossover to the alternate regimen.The primary outcome was symptom improvement assessed by numeric rating scale.Secondary outcomes included changes in quality of life (QoL) measured by the 36-item Short Form survey. ResultsAll 40 patients completed the trial.Overall, 75% reported symptom improvement: 65% in the amitriptyline group vs. 85% in the PPI group (P = 0.27).Both groups showed significant reductions in symptom severity (between-group P = 0.90) and improvements in QoL (physical and mental summary scores; P = 0.60 and 0.41, respectively).These improvements persisted post-crossover.A h e a d o f P r i n t 4 Conclusions Adding…
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.